What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
His main research concerns Colorectal cancer, Cancer research, Pathology, Internal medicine and KRAS.
Andreas Jung has included themes like Stem cell and Adenocarcinoma in his Colorectal cancer study.
His Cancer research study integrates concerns from other disciplines, such as Beta-catenin, Wnt signaling pathway, Catenin, Metastasis and Tumor progression.
He works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Proportional hazards model.
His studies deal with areas such as Cetuximab, Epidermal growth factor receptor and Genetic testing as well as KRAS.
His Cetuximab research is multidisciplinary, incorporating perspectives in Bevacizumab and Irinotecan, FOLFIRI.
His most cited work include:
- Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses (2867 citations)
- 5'-Triphosphate RNA Is the Ligand for RIG-I (1913 citations)
- Migrating cancer stem cells — an integrated concept of malignant tumour progression (1127 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Colorectal cancer, Internal medicine, Oncology, Cancer research and KRAS.
Andreas Jung focuses mostly in the field of Colorectal cancer, narrowing it down to matters related to Pathology and, in some cases, Adenocarcinoma.
Andreas Jung has researched Oncology in several fields, including Proportional hazards model, Biomarker, Oxaliplatin and Microsatellite instability.
His work carried out in the field of Cancer research brings together such families of science as Cancer, Tumor progression and Beta-catenin, Wnt signaling pathway, Catenin.
His Catenin research is multidisciplinary, incorporating elements of Tumor suppressor gene and Gene expression.
His KRAS study combines topics from a wide range of disciplines, such as Capecitabine and Exon.
He most often published in these fields:
- Colorectal cancer (53.31%)
- Internal medicine (49.70%)
- Oncology (44.28%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (49.70%)
- Oncology (44.28%)
- Colorectal cancer (53.31%)
In recent papers he was focusing on the following fields of study:
Andreas Jung focuses on Internal medicine, Oncology, Colorectal cancer, Bevacizumab and KRAS.
His research integrates issues of Personalized medicine and Microsatellite instability in his study of Internal medicine.
His Oncology study incorporates themes from Biomarker, Targeted therapy, Neuroblastoma RAS viral oncogene homolog and First line.
His studies in Colorectal cancer integrate themes in fields like Cancer research, MAPK/ERK pathway and Hazard ratio.
The study incorporates disciplines such as Cancer, Cancer stem cell, Stem cell, Wnt signaling pathway and Exon in addition to Cancer research.
His research in KRAS tackles topics such as Adenocarcinoma which are related to areas like Pathology, Surgical pathology, Adenoma and Allele frequency.
Between 2016 and 2021, his most popular works were:
- Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. (65 citations)
- In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components (50 citations)
- In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components (50 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His primary scientific interests are in Colorectal cancer, Internal medicine, Oncology, Cancer research and KRAS.
His research in Oncology intersects with topics in Mutation testing and External quality assessment.
His work deals with themes such as Cancer, Cancer stem cell, Stem cell, Wnt signaling pathway and MAPK/ERK pathway, which intersect with Cancer research.
His KRAS research integrates issues from Pathology, Gemcitabine, Pancreatic cancer and Adenocarcinoma.
The T790M research Andreas Jung does as part of his general Pathology study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science.
His study in Bevacizumab is interdisciplinary in nature, drawing from both Cetuximab, Randomized controlled trial and Irinotecan, FOLFIRI.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
